Which parameters differ in very old patients with chronic atrial fibrillation treated by anticoagulant or aspirin? Antithrombotic treatment of atrial fibrillation in the elderly

Fundamental and Clinical Pharmacology

Volumn 22, Issue 5, 2008, Pages 569-574

  Doucet, Jean ^a   Gréboval Furstenfeld, Emmanuelle ^a   Tavildari, Alain ^a   M'bello, Luc ^b   Delaunay, Olympe ^a   Pesqué, Thierry ^b   Moirot, P ^a   Mouton Schleifer, Dominique ^a  

^a ROUEN UNIVERSITY HOSPITAL   (France)

^b Centre Hospitalier Général   (France)

Author keywords

Anticoagulant; Aspirin; Atrial fibrillation; Elderly

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K;

AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CHI SQUARE TEST; CLINICAL TRIAL; COMORBIDITY; DEMENTIA; DRUG CHOICE; FALL RISK; FEMALE; GERIATRIC ASSESSMENT; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HEART DISEASE; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MINI MENTAL STATE EXAMINATION; MORTALITY; NUTRITIONAL DISORDER; NUTRITIONAL STATUS; PARAMETER; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SCORING SYSTEM; SOCIAL ISOLATION; STUDENT T TEST; SYSTOLIC BLOOD PRESSURE; THROMBOEMBOLISM; THROMBOPHLEBITIS; VALVULAR HEART DISEASE; VERY ELDERLY; WALKING; WALKING DIFFICULTY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; CHRONIC DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PROSPECTIVE STUDIES; RISK FACTORS; VITAMIN K;

EID: 52449119284     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2008.00629.x     Document Type: Article

References (20)

1. Aronow W.S., Ahn C., Gutstein H. Prevalence of atrial fibrillation and association of atrial fibrillation with prior and new thromboembolic stroke in older patients. J. Am. Geriatr. Soc. (1996) 44 521 523.
2. Wolf P.A., Abbott R.D., Kannel W.B. Atrial fibrillation is an independent risk factor for stroke: the Framingham Study. Stroke (1991) 22 983 988.
3. Petersen P., Boysen G., Godtfredsen J. et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet (1989) 1 175 179.
4. Hart R.G., Halperin J.L., Pearce L.A. et al., Stroke Prevention in Atrial Fibrillation Investigators. Lessons from the Stroke Prevention in Atrial Fibrillation trials. Ann. Intern. Med. (2003) 138 831 838.
5. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N. Engl. J. Med. (1990) 29 323.
6. Garcia D.A., Hylek E.M. Antithrombotic therapy in atrial fibrillation. Clin. Geriatr. Med. (2006) 22 155 166.
7. Bailey R.D., Hart R.G., Benavente O. et al. Recurrent brain hemorrhage is more frequent than ischemic stroke after intracranial hemorrhage. Neurology (2001) 56 773 777.
8. Gage B.F., Waterman A.D., Shannon W. et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA (2001) 285 2864 2870.
9. Beyth R.J., Quinn L.M., Landefeld C.S. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am. J. Med. (1998) 105 91 99.
10. Fang M.C., Stafford R.S., Ruskin J.N. et al. National trends in antiarrhythmic and antithrombotic medication use in atrial fibrillation. Arch. Intern. Med. (2004) 164 55 60.
11. Bungard T.J., Ghali W.A., McAlister F.A. et al. The relative importance of barriers to the prescription of warfarin for nonvalvular atrial fibrillation. Can. J. Cardiol. (2003) 19 280 284.
12. Beyth R.J., Antani M.R., Covinsky K.E. et al. Why isn't warfarin prescribed to patients with nonrheumatic atrial fibrillation? J. Gen. Intern. Med. (1996) 11 721 728.
13. Gage B.F., Boechler M., Doggette A.L. et al. Adverse outcomes and predictors of underuse of antithrombotic therapy in medicare beneficiaries with chronic atrial fibrillation. Stroke (2000) 31 822 827.
14. Beyth R.J., Landefeld C.S. Anticoagulants in older patients. A safety perspective. Drugs Aging (1995) 6 45 54.
15. Man-Son-Hing M., Nichol G., Lau A. et al. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch. Intern. Med. (1999) 159 677 685.
16. Samsa G.P., Matchar D.B., Goldstein L.B. et al. Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 communities. Arch. Intern. Med. (2000) 160 967 973.
17. Frost L., Johnsen S.P., Pedersen L. et al. Atrial fibrillation or flutter and stroke: a Danish population-based study of the effectiveness of oral anticoagulation in clinical practice. J. Intern. Med. (2002) 252 64 69.
18. Lau E., Bungard T.J., Tsuyuki R.T. Stroke prophylaxis in institutionalized elderly patients with atrial fibrillation. J. Am. Geriatr. Soc. (2004) 52 428 433.
19. Fuster V., Ryden L.E., Asinger R.W. et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. Circulation (2001) 104 2118 2150.
20. Man-Son-Hing M., Laupacis A. Anticoagulant-related bleeding in older persons with atrial fibrillation: physicians' fears often unfounded. Arch. Intern. Med. (2003) 163 1580 1586.